OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 131 filers reported holding OCULAR THERAPEUTIX INC in Q1 2022. The put-call ratio across all filers is 1.09 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | -40.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2023 | $10 | -9.1% | 2,000 | 0.0% | 0.00% | – |
| Q1 2023 | $11 | +83.3% | 2,000 | 0.0% | 0.00% | – |
| Q4 2022 | $6 | -99.9% | 2,000 | 0.0% | 0.00% | – |
| Q3 2022 | $8,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2022 | $8,000 | -20.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2022 | $10,000 | -28.6% | 2,000 | 0.0% | 0.00% | – |
| Q4 2021 | $14,000 | -50.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2021 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2021 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2020 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q3 2020 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2020 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2020 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2019 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q3 2019 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2019 | $28,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2019 | $28,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |